HHS Public Access Author manuscript Author Manuscript

N Engl J Med. Author manuscript; available in PMC 2017 March 09. Published in final edited form as: N Engl J Med. 2016 July 14; 375(2): 134–142. doi:10.1056/NEJMoa1515725.

Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting

Author Manuscript

Rudolph M. Navari, M.D., Rui Qin, Ph.D., Kathryn J. Ruddy, M.D., Heshan Liu, Ph.D., Steven F. Powell, M.D., Madhuri Bajaj, M.D., Leah Dietrich, M.D., David Biggs, M.D., Jacqueline M. Lafky, M.S., and Charles L. Loprinzi, M.D. Indiana University School of Medicine–South Bend, South Bend (R.M.N.); Alliance Statistics and Data Center, Mayo Clinic (R.Q., H.L.), and Mayo Clinic (K.J.R., J.M.L., C.L.L.), Rochester, MN; Sanford NCORP (National Cancer Institute Community Oncology Research Program) of the North Central Plains, Sioux Falls, SD (S.F.P.); Illinois Cancer Care–Peoria, Peoria (M.B.); Gundersen Lutheran Medical Center, La Crosse, WI (L.D.); and Delaware–Christiana Care NCORP, Newark, DE (D.B.)

Abstract BACKGROUND—We examined the efficacy of olanzapine for the prevention of nausea and vomiting in patients receiving highly emetogenic chemotherapy.

Author Manuscript

METHODS—In a randomized, double-blind, phase 3 trial, we compared olanzapine with placebo, in combination with dexamethasone, aprepitant or fosaprepitant, and a 5-hydroxytryptamine type 3–receptor antagonist, in patients with no previous chemotherapy who were receiving cisplatin (≥70 mg per square meter of body-surface area) or cyclophosphamide–doxorubicin. The doses of the three concomitant drugs administered before and after chemotherapy were similar in the two groups. The two groups received either 10 mg of olanzapine orally or matching placebo daily on days 1 through 4. Nausea prevention was the primary end point; a complete response (no emesis and no use of rescue medication) was a secondary end point.

Author Manuscript

RESULTS—In the analysis, we included 380 patients who could be evaluated (192 assigned to olanzapine, and 188 to placebo). The proportion of patients with no chemotherapy-induced nausea was significantly greater with olanzapine than with placebo in the first 24 hours after chemotherapy (74% vs. 45%, P = 0.002), the period from 25 to 120 hours after chemotherapy (42% vs. 25%, P = 0.002), and the overall 120-hour period (37% vs. 22%, P = 0.002). The complete-response rate was also significantly increased with olanzapine during the three periods: 86% versus 65% (P

Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting.

We examined the efficacy of olanzapine for the prevention of nausea and vomiting in patients receiving highly emetogenic chemotherapy...
698KB Sizes 12 Downloads 8 Views

Recommend Documents

Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting.
Olanzapine is an atypical antipsychotic agent of the thiobenzodiazepine class. It blocks multiple neurotransmitter receptors including dopaminergic at D1, D2, D3, D4 brain receptors, serotonergic at 5-HT2a, 5-HT2c, 5-HT3, 5-HT6 receptors, catecholami

Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review.
Newer drugs incorporated in prophylactic regimens for chemotherapy-induced nausea and vomiting (CINV) have resulted in significantly reduced rates of this feared complication of cytotoxic chemotherapy. However, both delayed chemotherapy-induced nause

Alternative Therapies for the Prevention of Postoperative Nausea and Vomiting.
Postoperative nausea and vomiting (PONV) is a complication affecting between 20 and 40% of all surgery patients, with high-risk patients experiencing rates of up to 80%. Recent studies and publications have shed light on the uses of alternative treat

Caffeine for the prevention of postoperative nausea and vomiting.
Postoperative nausea and vomiting (PONV) is common after ambulatory surgery performed under general anesthesia. Anecdotal evidence suggests that caffeine may be useful in preventing PONV.

Olanzapine for chemotherapy-induced nausea and vomiting: systematic review and meta-analysis.
Chemotherapy induced nausea and vomiting (CINV) remains the most distressing event in patients receiving highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC).

Effectiveness of Olanzapine Combined with Ondansetron in Prevention of Chemotherapy-Induced Nausea and Vomiting of Non-small Cell Lung Cancer.
The objective of this study is to compare the effectiveness of olanzapine combined with ondansetron or ondansetron alone in preventing chemotherapy-induced nausea and vomiting (CINV) of non-small cell lung cancer (NSCLC). A total of 84 NSCLC patients

Prevention and management of chemotherapy-induced nausea and vomiting.
Nausea and vomiting are among the most frequently experienced toxic side-effects associated with chemotherapy. Although nausea and vomiting can result from surgery or radiotherapy, chemotherapy-induced nausea and vomiting (CINV) is potentially the mo